Skip to content
Screener

Ironwood Pharmaceuticals IRWD Collaborative Arrangements — Contract With Customer Liability Noncurrent

Similar metrics at other companies

Wrap Technologies logo
WRAPCustomer Deposits — Contract With Customer Liability Noncurrent
$0
Tidewater logo
TDWVessel — Contract With Customer Liability Noncurrent
$2.5M
Aclaris Therapeutics logo
ACRSRoyalty — Contract With Customer Liability Noncurrent
$14.3M-21.4%
Eton Pharmaceuticals, Inc. logo
ETONIncrelex — Contract With Customer Liability Noncurrent
$1.76M
Maui Land & Pineapple logo
MLPExcluding Deposits — Contract With Customer Liability Noncurrent
$1.07M-11.2%
Maui Land & Pineapple logo
MLPMember Deposits — Contract With Customer Liability Noncurrent
$1.93M-0.6%

Other financials

Income statement

See full
Revenue$113.0M+32.6%
Operating income$79.3M+75.0%
Net income$51.3M+117%
EPS (diluted)$0.31+121%

Balance sheet

See full
Cash & equivalents$79.1M-14.8%
Total debt$11.9M-94.4%
Total equity-$161.8M+47.5%
Total assets$285.1M-16.9%

Cash flow

See full
Operating cash flow$58.3M
CapEx-
Free cash flow$74.6M+390%

Valuation

See full
Market cap$669.22M+395%
Enterprise value$601.96M+135%
P/E5.2×
P/S1.7×+1.3×

Profitability

See full
Gross margin99.2%
Operating margin60.1%+36.4pp
Net margin33.4%+31.1pp
FCF margin24.7%-11.1pp

Returns & leverage

See full
Return on equity29.7%-138pp
Debt / equity-0.5×
Current ratio6.1×+5.2×

Where this comes from

Reported directly by Ironwood Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The source filing: Ironwood Pharmaceuticals’s 10-K, filed February 26, 2026.

Filed
Feb 26, 2026, 4:09 PM EST
Fiscal year
FY2025
Accession
0001104659-26-020489

The Company recognized a net reduction of revenue in the amount of $1.9 million during the year ended December 31, 2025, related to development activities. The Company recognized $2.2 million of revenue during the year ended December 31, 2024. As of December 31, 2025, current deferred revenue of $1.1 million and non-current deferred revenue of $5.3 million is reported within accrued expenses and other current liabilities and other liabilities, respectively, on the consolidated balance sheets. Deferred revenue related to development activities is expected to be recognized over the course of the development activities, which are anticipated to be substantially complete by 2030.

Item 16. Form 10-K Summary

FAQ

What is Ironwood Pharmaceuticals's collaborative arrangements — contract with customer liability noncurrent?
Ironwood Pharmaceuticals (IRWD) reported collaborative arrangements — contract with customer liability noncurrent of $5.3M in Q4 2025.
What does collaborative arrangements — contract with customer liability noncurrent mean?
This represents the portion of deferred revenue or performance obligations from collaborative arrangements that are expected to be satisfied beyond the next twelve months. It reflects long-term contractual commitments and the timing of future performance obligations in multi-year partnerships. Monitoring this helps investors understand the long-term revenue pipeline associated with existing collaborative agreements.

Ask your AI about Ironwood Pharmaceuticals's collaborative arrangements — contract with customer liability noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude